Derek Tang

1.3k total citations
75 papers, 943 citations indexed

About

Derek Tang is a scholar working on Genetics, Hematology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Derek Tang has authored 75 papers receiving a total of 943 indexed citations (citations by other indexed papers that have themselves been cited), including 41 papers in Genetics, 35 papers in Hematology and 19 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Derek Tang's work include Myeloproliferative Neoplasms: Diagnosis and Treatment (19 papers), Hemoglobinopathies and Related Disorders (17 papers) and Advanced Breast Cancer Therapies (16 papers). Derek Tang is often cited by papers focused on Myeloproliferative Neoplasms: Diagnosis and Treatment (19 papers), Hemoglobinopathies and Related Disorders (17 papers) and Advanced Breast Cancer Therapies (16 papers). Derek Tang collaborates with scholars based in United States, United Kingdom and Italy. Derek Tang's co-authors include James Piercy, Denise Globe, Vaishali Patel, Danielle Colayco, Edward P. Armstrong, Ayal A. Aizer, Jeannie K. Lee, Daniel C. Malone, Terri Warholak and Neel Shah and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer Research.

In The Last Decade

Derek Tang

69 papers receiving 929 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Derek Tang United States	19	266	249	224	217	207	75	943
Sarika Ogale United States	18	102 0.4×	460 1.8×	166 0.7×	181 0.8×	257 1.2×	74	1.2k
Hester H. van Boven Netherlands	16	78 0.3×	296 1.2×	111 0.5×	287 1.3×	133 0.6×	30	1.0k
Brijesh Arora India	17	265 1.0×	108 0.4×	205 0.9×	246 1.1×	181 0.9×	67	1.0k
Luiz Fernando Lopes Brazil	18	107 0.4×	166 0.7×	283 1.3×	210 1.0×	195 0.9×	74	1.0k
Sophie Taque France	14	86 0.3×	53 0.2×	196 0.9×	57 0.3×	104 0.5×	36	929
Franca Fossati Bellani Italy	18	128 0.5×	56 0.2×	343 1.5×	112 0.5×	262 1.3×	40	1.1k
G. Bánfi Italy	19	90 0.3×	256 1.0×	215 1.0×	148 0.7×	67 0.3×	40	1.1k
Farzana Pashankar United States	20	448 1.7×	57 0.2×	174 0.8×	337 1.6×	106 0.5×	75	1.3k
J J Shuster United States	25	205 0.8×	70 0.3×	245 1.1×	288 1.3×	334 1.6×	34	1.6k
Michael O’Rorke United Kingdom	15	175 0.7×	76 0.3×	93 0.4×	135 0.6×	272 1.3×	31	982

Countries citing papers authored by Derek Tang

Since Specialization

Citations

This map shows the geographic impact of Derek Tang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Derek Tang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Derek Tang more than expected).

Fields of papers citing papers by Derek Tang

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Derek Tang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Derek Tang. The network helps show where Derek Tang may publish in the future.

Co-authorship network of co-authors of Derek Tang

This figure shows the co-authorship network connecting the top 25 collaborators of Derek Tang. A scholar is included among the top collaborators of Derek Tang based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Derek Tang. Derek Tang is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Mauro, Michael J., Rüdiger Hehlmann, Loretta A. Williams, et al.. (2025). Five-year molecular response and overall survival with first- and second-generation tyrosine kinase inhibitors in patients with chronic myeloid leukemia in the chronic phase: a prospective, observational study – SIMPLICITY. Leukemia & lymphoma. 66(9). 1615–1624. 1 indexed citations

Mascarenhas, John, et al.. (2024). The Use of Fedratinib (FEDR) for Myelofibrosis (MF) As a Potential Bridge to Hematopoietic Stem Cell Transplantation (HSCT) after Ruxolitinib (RUX) Failure: Real-World Assessment of Treatment Characteristics and Spleen, Symptoms, and Hematologic Response. Transplantation and Cellular Therapy. 30(2). S372–S372. 1 indexed citations

Andritsos, Leslie A., Ali McBride, Derek Tang, et al.. (2024). Real-world impact of luspatercept on red blood cell transfusions among patients with myelodysplastic syndromes: A United States healthcare claims database study. Leukemia Research. 148. 107624–107624. 2 indexed citations

Ball, Brian, et al.. (2024). MDS-059 Real-World Impact of Luspatercept Versus Erythropoiesis-Stimulating Agents (ESAs) on the Healthcare Resource Utilization (HRU) of Patients With Myelodysplastic Syndromes (MDS) in the United States (US). Clinical Lymphoma Myeloma & Leukemia. 24. S385–S385.

Buckstein, Rena, Karen Yee, Michelle Geddes, et al.. (2023). The burden of red blood cell transfusions in patients with lower-risk myelodysplastic syndromes and ring sideroblasts: an analysis of the prospective MDS-CAN registry. Leukemia & lymphoma. 64(3). 651–661. 3 indexed citations

Lee, Hans C., Karthik Ramasamy, Katja Weisel, et al.. (2022). Treatment Patterns, Survival, Quality of Life, and Healthcare Resource Use Among Patients With Triple-Class Refractory Multiple Myeloma in US Clinical Practice: Findings From the Connect MM Disease Registry. Clinical Lymphoma Myeloma & Leukemia. 23(2). 112–122. 6 indexed citations

Martin, Antony P., Farrukh Shah, Lisa Maher, et al.. (2022). Health state utilities for beta-thalassemia: a time trade-off study. The European Journal of Health Economics. 24(1). 27–38.

Santini, Valeria, Aristoteles Giagounidis, Conrado Franco‐Villalobos, et al.. (2022). Impact of Lenalidomide Treatment on Overall Survival in Patients With Lower-Risk, Transfusion-Dependent Myelodysplastic Syndromes. Clinical Lymphoma Myeloma & Leukemia. 22(9). e874–e883. 5 indexed citations

Schroeder, Thomas, et al.. (2021). Association between red blood cell transfusion dependence and burden in patients with myelodysplastic syndromes: A systematic literature review and meta‐analysis. European Journal Of Haematology. 107(1). 3–23. 12 indexed citations

10.

Mollon, Lea, Elizabeth J. Anderson, Terri Warholak, et al.. (2019). A Systematic Literature Review of the Prognostic and Predictive Value of PIK3CA Mutations in HR+/HER2− Metastatic Breast Cancer. Clinical Breast Cancer. 20(3). e232–e243. 32 indexed citations

11.

Krohe, Meaghan, et al.. (2019). Understanding key symptoms, side effects, and impacts of HR+/HER2- advanced breast cancer: qualitative study findings. Journal of Patient-Reported Outcomes. 3(1). 10–10. 10 indexed citations

12.

Krohe, Meaghan, et al.. (2019). Content validity of the National Comprehensive Cancer Network – Functional Assessment of Cancer Therapy – Breast Cancer Symptom Index (NFBSI-16) and Patient-Reported Outcomes Measurement Information System (PROMIS) Physical Function Short Form with advanced breast cancer patients. Health and Quality of Life Outcomes. 17(1). 92–92. 19 indexed citations

13.

Mistry, Rohit, Gaurav Suri, Kate Young, et al.. (2018). Cost-Effectiveness of Ribociclib plus Letrozole Versus Palbociclib plus Letrozole and Letrozole Monotherapy in the First-Line Treatment of Postmenopausal Women with HR+/HER2- Advanced or Metastatic Breast Cancer: A U.S. Payer Perspective. Journal of Managed Care & Specialty Pharmacy. 24(6). 514–523. 67 indexed citations

14.

Ayyagari, Rajeev, Derek Tang, Oscar Patterson‐Lomba, et al.. (2018). Progression-free Survival With First-line Endocrine-based Therapies Among Postmenopausal Women With HR+/HER2– Metastatic Breast Cancer:. Clinical Therapeutics. 40(4). 628–639.e3. 9 indexed citations

15.

Gu, Tao, Neel Shah, Gaurav Deshpande, Derek Tang, & D. Eisenberg. (2016). Comparing Biologic Cost Per Treated Patient Across Indications Among Adult US Managed Care Patients: A Retrospective Cohort Study. Drugs - Real World Outcomes. 3(4). 369–381. 30 indexed citations

16.

Tang, Derek, Danielle Colayco, James Piercy, et al.. (2014). Impact of urinary incontinence on health-related quality of life, daily activities, and healthcare resource utilization in patients with neurogenic detrusor overactivity. BMC Neurology. 14(1). 74–74. 49 indexed citations

17.

Tang, Derek, Adrienne M. Gilligan, & Klaus Romero. (2013). Economic Burden and Disparities in Healthcare Resource Use Among Adult Patients with Cardiac Arrhythmia. Applied Health Economics and Health Policy. 12(1). 59–71. 30 indexed citations

18.

Tang, Derek, et al.. (2013). A Systematic Review of Economic Studies on Biological Agents Used to Treat Crohn’s Disease. Inflammatory Bowel Diseases. 19(12). 2673–2694. 28 indexed citations

19.

Tang, Derek & Daniel C. Malone. (2012). A Network Meta-Analysis on the Efficacy of Serotonin Type 3 Receptor Antagonists Used in Adults During the First 24 Hours for Postoperative Nausea and Vomiting Prophylaxis. Clinical Therapeutics. 34(2). 282–294. 25 indexed citations

20.

Tang, Derek, et al.. (2012). Health Care Expenditures, Hospitalizations, and Productivity Associated With Cancer in US Employer Settings. Journal of Occupational and Environmental Medicine. 54(12). 1453–1460. 7 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact